NCT01217086View on ClinicalTrials.gov

Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)

PHASE3CompletedINTERVENTIONAL

Enrollment

617

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

July 31, 2012

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Infliximab

Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.

Trial Locations (1)

Unknown

Hanyang University Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Celltrion

INDUSTRY